Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: A SEER-based Study

European Urology

Volumn 67, Issue 1, 2015, Pages 3-6

  Fossati, Nicola ^a,b   Trinh, Quoc Dien ^c   Sammon, Jesse ^d   Sood, Akshay ^d   Larcher, Alessandro ^b,e   Sun, Maxine ^e   Karakiewicz, Pierre ^e   Guazzoni, Giorgio ^b   Montorsi, Francesco ^b   Briganti, Alberto ^b   Menon, Mani ^d   Abdollah, Firas ^d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Cancer specific survival; Metastasis; Primary tumor treatment; Prostate cancer; Radiation therapy; Radical prostatectomy

Indexed keywords

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER THERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; LOCAL THERAPY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; PATIENT SELECTION; PELVIS LYMPH NODE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; AGE; BRACHYTHERAPY; CANCER GRADING; CANCER REGISTRY; CANCER STAGING; MIDDLE AGED; MORTALITY; NUMBERS NEEDED TO TREAT; PATHOLOGY; PROSTATIC NEOPLASMS; SURVIVAL RATE; WATCHFUL WAITING;

ANTIANDROGEN;

AGE FACTORS; AGED; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; NUMBERS NEEDED TO TREAT; PATIENT SELECTION; PROSTATECTOMY; PROSTATIC NEOPLASMS; SEER PROGRAM; SURVIVAL RATE; WATCHFUL WAITING;

EID: 84922121592     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.08.056     Document Type: Article

References (9)

1. A. Heidenreich, P.J. Bastian, and J. Bellmunt EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 65 2014 467 479
2. S.H. Culp, P.F. Schellhammer, and M.B. Williams Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study Eur Urol 65 2014 1058 1066
3. R.C. Flanigan, S.E. Salmon, and B.A. Blumenstein Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 2001 1655 1659
4. L.K.F. Temple, L. Hsieh, W.D. Wong, L. Saltz, and D. Schrag Use of surgery among elderly patients with stage IV colorectal cancer J Clin Oncol 22 2004 3475 3484
5. R.N. Kaplan, R.D. Riba, and S. Zacharoulis VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche Nature 438 2005 820 827
6. B. Psaila, and D. Lyden The metastatic niche: adapting the foreign soil Nat Rev Cancer 9 2009 285 293
7. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T Immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
8. J.S. de Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
9. N.D. James, M.R. Sydes, and M.D. Mason Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial Lancet Oncol 13 2012 549 558